| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.051 | 11.899 | 9.875 | 0 | 0 | 966 | 0 | 2.682 | 2.674 | 0 |
| Total Income - EUR | 1.051 | 11.899 | 9.875 | 0 | 0 | 966 | 0 | 2.682 | 2.674 | 0 |
| Total Expenses - EUR | 886 | 1.331 | 6.695 | 0 | 0 | 814 | 0 | 1.087 | 1.084 | 0 |
| Gross Profit/Loss - EUR | 165 | 10.568 | 3.181 | 0 | 0 | 152 | 0 | 1.595 | 1.590 | 0 |
| Net Profit/Loss - EUR | 134 | 10.212 | 2.884 | 0 | 0 | 123 | 0 | 1.514 | 1.510 | 0 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Aleser Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 17.194 | 27.168 | 29.370 | 28.831 | 28.273 | 15.800 | 15.264 | 28.603 | 28.516 | 28.357 |
| Inventories | 0 | 775 | 762 | 748 | 733 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 8.204 | 6.393 | 171 | 161 | 27.508 | 15.798 | 15.262 | 26.470 | 26.390 | 26.242 |
| Cash | 8.990 | 20.000 | 28.437 | 27.922 | 31 | 2 | 2 | 2.133 | 2.126 | 2.114 |
| Shareholders Funds | 16.868 | 26.907 | 29.336 | 28.798 | 28.125 | 15.355 | 15.015 | 28.578 | 28.491 | 28.332 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 326 | 260 | 34 | 34 | 148 | 445 | 250 | 25 | 25 | 25 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Aleser Pharma Srl